Company ValiRx Plc London S.E.
Equities
GB00B23N9136
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- GBX | - |
Apr. 22 | Valirx plc Announces Directorate Changes | CI |
Mar. 21 | ValiRx inks evaluation deal with Imperial College London for research | AN |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Suzanne Dilly
CEO | Chief Executive Officer | 46 | - |
Gerald Desler
DFI | Director of Finance/CFO | 79 | 06-08-31 |
Chief Tech/Sci/R&D Officer | - | 22-09-07 | |
Kumar Nawani
COO | Chief Operating Officer | - | - |
Mark Treharne
PRN | Corporate Officer/Principal | - | 20-09-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Gerald Desler
DFI | Director of Finance/CFO | 79 | 06-08-31 |
Kevin Cox
CHM | Chairman | 65 | 20-06-25 |
Director/Board Member | 57 | Feb. 28 | |
Suzanne Dilly
CEO | Chief Executive Officer | 46 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 132,348,673 | 110,208,233 ( 83.27 %) | 0 | 83.27 % |
Company contact information
ValiRx Plc
Eliot Park Innovation Centre 4 Barling Way
CV10 7RH, Nuneaton
+44 24 7679 6496
http://www.valirx.comSector
1st Jan change | Capi. | |
---|---|---|
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- VAL Stock
- Stock
- Company ValiRx Plc